Scholarlink

Background <p>The management of Parkinson’s disease (PD) remains challenging owing to the limitations of current therapies. Although rasagiline (RASA), a monoamine oxidase-B (MAO-B) inhibitor, offers advantages over levodopa, its efficacy as a monotherapy is moderate. Pueraria root (PR), a traditional East Asian medicine, has demonstrated neuroprotective potential against several neurodegenerative conditions. This study investigated the pharmacodynamic and pharmacokinetic interactions between RASA and PR to evaluate their potential as a combination therapy for PD.</p> Methods <p>We examined synergistic effects on MAO-B inhibition by performing MAO-B enzyme reaction assay. We measured the cell viability for evaluating the neuroprotective effects of their co-administration against 6-OHDA-induced toxicity in PC12 cells. For investigating the interaction of drug metabolism, CYP450 expressions were measured in hepatocytes using quantitative real-time polymerase chain reaction.</p> Results <p>Concentration-dependent studies revealed a significant synergistic inhibition of MAO-B activity when RASA and PR were co-administered at specific ratios, as confirmed by combination index analysis. Although neither of the two drugs alone provided significant neuroprotection at concentrations effective for MAO-B inhibition, their co-administration significantly increased the survival of in 6-OHDA-treated cells. Importantly, investigation of CYP450 metabolism demonstrated minimal interference between these compounds, with no significant alterations in the expression patterns of relevant CYP isoforms during co-administration.</p> Conclusion <p>These findings suggest that the RASA – PR combination offers enhanced therapeutic potential through synergistic effects, while maintaining favourable metabolic compatibility. This study establishes a scientific foundation for integrating traditional herbal medicine with conventional pharmaceuticals in PD management, potentially allowing for reduced conventional drug dosages while improving therapeutic outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Interaction between rasagiline and Pueraria radix in in vitro models of parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月4日

查看全文
  • Eugene Huh,
  • Jin Hee Kim,
  • Seungmin Lee,
  • Myung Sook Oh

摘要

Background

The management of Parkinson’s disease (PD) remains challenging owing to the limitations of current therapies. Although rasagiline (RASA), a monoamine oxidase-B (MAO-B) inhibitor, offers advantages over levodopa, its efficacy as a monotherapy is moderate. Pueraria root (PR), a traditional East Asian medicine, has demonstrated neuroprotective potential against several neurodegenerative conditions. This study investigated the pharmacodynamic and pharmacokinetic interactions between RASA and PR to evaluate their potential as a combination therapy for PD.

Methods

We examined synergistic effects on MAO-B inhibition by performing MAO-B enzyme reaction assay. We measured the cell viability for evaluating the neuroprotective effects of their co-administration against 6-OHDA-induced toxicity in PC12 cells. For investigating the interaction of drug metabolism, CYP450 expressions were measured in hepatocytes using quantitative real-time polymerase chain reaction.

Results

Concentration-dependent studies revealed a significant synergistic inhibition of MAO-B activity when RASA and PR were co-administered at specific ratios, as confirmed by combination index analysis. Although neither of the two drugs alone provided significant neuroprotection at concentrations effective for MAO-B inhibition, their co-administration significantly increased the survival of in 6-OHDA-treated cells. Importantly, investigation of CYP450 metabolism demonstrated minimal interference between these compounds, with no significant alterations in the expression patterns of relevant CYP isoforms during co-administration.

Conclusion

These findings suggest that the RASA – PR combination offers enhanced therapeutic potential through synergistic effects, while maintaining favourable metabolic compatibility. This study establishes a scientific foundation for integrating traditional herbal medicine with conventional pharmaceuticals in PD management, potentially allowing for reduced conventional drug dosages while improving therapeutic outcomes.